Travere Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 53.5 million compared to USD 68.22 million a year ago. Net loss was USD 69.66 million compared to USD 35.64 million a year ago. Basic loss per share from continuing operations was USD 1.09 compared to USD 0.59 a year ago. Diluted loss per share from continuing operations was USD 1.09 compared to USD 0.59 a year ago.
For the nine months, revenue was USD 156.15 million compared to USD 170.24 million a year ago. Net loss was USD 212.66 million compared to USD 128.52 million a year ago. Basic loss per share from continuing operations was USD 3.34 compared to USD 2.17 a year ago. Diluted loss per share from continuing operations was USD 3.34 compared to USD 2.17 a year ago.